Adoptive T-Cell Therapy for EBV-Associated Post-Transplant Lymphoproliferative Disease
暂无分享,去创建一个
[1] Zhensheng Liu,et al. Generation of autologous Epstein-Barr virus-specific cytotoxic T cells for adoptive immunotherapy in solid organ transplant recipients. , 2001, Transplantation.
[2] Jaap M Middeldorp,et al. Frequent monitoring of Epstein-Barr virus DNA load in unfractionated whole blood is essential for early detection of posttransplant lymphoproliferative disease in high-risk patients. , 2001, Blood.
[3] J. Wingard,et al. Treatment of post-transplant lymphoproliferative disease with induction chemotherapy followed by haploidentical peripheral blood stem cell transplantation and Rituximab , 2001, Bone Marrow Transplantation.
[4] J. D. de Fijter,et al. SUCCESSFUL OUTCOME WITH A “QUINTUPLE APPROACH” OF POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDER , 1999, Transplantation.
[5] T. Barbui,et al. Anti-CD20 antibody (rituximab) administration in patients with late occurring lymphomas after solid organ transplant. , 2001, Haematologica.
[6] D. Schendel,et al. Ex vivo generation of cytotoxic T lymphocytes specific for one or two distinct viruses for the prophylaxis of patients receiving an allogeneic bone marrow transplant , 2001, Bone Marrow Transplantation.
[7] C. Ryan,et al. CD‐20 expression in post‐transplant lymphoproliferative disorders: Treatment with Rituximab , 2000, American journal of hematology.
[8] N. Ohkohchi,et al. Usefulness of quantitative real‐time polymerase chain reaction in following up patients with Epstein–Barr virus infection after liver transplantation , 2000, Clinical transplantation.
[9] R. Busuttil,et al. The effect of immunosuppression on posttransplant lymphoproliferative disease in pediatric liver transplant patients. , 2000, Transplantation.
[10] D. Crawford,et al. The role of EBV in post-transplant malignancies: a review , 2000, Journal of clinical pathology.
[11] G. Remuzzi,et al. Epstein-Barr virus-negative lymphoproliferate disorders in long-term survivors after heart, kidney, and liver transplant. , 2000, Transplantation.
[12] S. Swerdlow,et al. Epstein-Barr virus-negative post-transplant lymphoproliferative disorders: a distinct entity? , 2000, The American journal of surgical pathology.
[13] Zhensheng Liu,et al. CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem-cell transplantation. , 2000, Blood.
[14] M. Tiemann,et al. Epstein–Barr virus‐associatedpost‐transplant lymphoproliferative disease after bone marrow transplantation mimicking graft‐versus‐host disease , 2000 .
[15] F. Baldanti,et al. High Levels of Epstein-Barr Virus DNA in Blood of Solid-Organ Transplant Recipients and Their Value in Predicting Posttransplant Lymphoproliferative Disorders , 2000, Journal of Clinical Microbiology.
[16] I. Ernberg,et al. Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: prophylactic infusion of EBV-specific cytotoxic T cells. , 2000, Blood.
[17] L. Swinnen,et al. Diagnosis and treatment of transplant-related lymphoma. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.
[18] V. Leblond,et al. Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.
[19] T. Starzl,et al. Posttransplant lymphoproliferative disorders in adult and pediatric renal transplant patients receiving tacrolimus-based immunosuppression. , 1999, Transplantation.
[20] R. Gascoyne,et al. Treatment of post-transplant lymphoproliferative disease with rituximab monoclonal antibody after lung transplantation , 1999, The Lancet.
[21] L. Swinnen. Overview of posttransplant B-cell lymphoproliferative disorders. , 1999, Seminars in oncology.
[22] V. Scantlebury,et al. Epstein-Barr virus-related disorders in children undergoing renal transplantation with tacrolimus-based immunosuppression. , 1999, Transplantation.
[23] E. Jaffe,et al. Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. , 1999, Blood.
[24] Jaap M Middeldorp,et al. Monitoring of Epstein-Barr Virus DNA Load in Peripheral Blood by Quantitative Competitive PCR , 1999, Journal of Clinical Microbiology.
[25] Richard E. Slaughter,et al. Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[26] D. Crawford,et al. THE ROLE OF ADOPTIVE IMMUNOTHERAPY IN THE PREVENTION AND TREATMENT OF LYMPHOPROLIFERATIVE DISEASE FOLLOWING TRANSPLANTATION , 1999, British journal of haematology.
[27] D. Czerwinski,et al. Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[28] J Wagner,et al. B cell lymphoproliferative disorders following hematopoietic stem cell transplantation: risk factors, treatment and outcome , 1999, Bone Marrow Transplantation.
[29] G. Mazariegos,et al. Serial measurement of Epstein-Barr viral load in peripheral blood in pediatric liver transplant recipients during treatment for posttransplant lymphoproliferative disease. , 1998, Transplantation.
[30] B. Wood,et al. Interferon-alpha treatment of posttransplant lymphoproliferative disorder in recipients of solid organ transplants. , 1998, Transplantation.
[31] A. Fischer,et al. Anti-B-cell monoclonal antibody treatment of severe posttransplant B-lymphoproliferative disorder: prognostic factors and long-term outcome. , 1998, Blood.
[32] A. Burroughs,et al. Reconstitution of EBV-specific T cell immunity in solid organ transplant recipients. , 1998, Journal of immunology.
[33] G. Hale,et al. Risks of developing Epstein-Barr virus-related lymphoproliferative disorders after T-cell-depleted marrow transplants. CAMPATH Users. , 1998, Blood.
[34] T. Greiner,et al. Treatment of post-transplant lymphoproliferative disease (PTLD) following solid organ transplantation with low-dose chemotherapy. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.
[35] F. Davi,et al. Posttransplant lymphoproliferative disorders not associated with Epstein-Barr virus: a distinct entity? , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[36] D. Srivastava,et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. , 1998, Blood.
[37] H. Antunes,et al. Early signs and risk factors for the increased incidence of Epstein-Barr virus-related posttransplant lymphoproliferative diseases in pediatric liver transplant recipients treated with tacrolimus. , 1997, Transplantation.
[38] A. Kliger,et al. Reduced incidence of Epstein-Barr virus-associated posttransplant lymphoproliferative disorder using preemptive antiviral therapy. , 1997, Transplantation.
[39] B. Griffith,et al. Posttransplantation lymphoproliferative disorders in pediatric thoracic organ recipients. , 1997, The Journal of pediatrics.
[40] K. Pollok,et al. Treatment of posttransplant lymphoproliferative disease in the central nervous system of a lung transplant recipient using allogeneic leukocytes. , 1997, Transplantation.
[41] H. Heslop,et al. Adoptive cellular immunotherapy for EBV lymphoproliferative diseases , 1997 .
[42] K. Lucas,et al. Biology and adoptive cell therapy of Epstein‐Barr virus‐associated lymphoproliferative disorders in recipients of marrow allografts , 1997, Immunological reviews.
[43] J. Reyes,et al. Use of quantitative competitive PCR to measure Epstein-Barr virus genome load in the peripheral blood of pediatric transplant patients with lymphoproliferative disorders , 1997, Journal of clinical microbiology.
[44] T. Starzl,et al. Autologous lymphokine-activated killer cell therapy of Epstein-Barr virus-positive and -negative lymphoproliferative disorders arising in organ transplant recipients. , 1997, Transplantation.
[45] K. Cornetta,et al. Posttransplantation lymphoproliferative disorders in bone marrow transplant recipients are aggressive diseases with a high incidence of adverse histologic and immunobiologic features. , 1997, American journal of clinical pathology.
[46] D. Moss,et al. Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection. , 1997, Annual review of immunology.
[47] H. Koeppen,et al. Posttransplant lymphoproliferative disease in pediatric liver transplantation. Interplay between primary Epstein-Barr virus infection and immunosuppression. , 1996, Transplantation.
[48] J. Hermans,et al. Risk factors for developing EBV-related B cell lymphoproliferative disorders (BLPD) after non-HLA-identical BMT in children. , 1996, Bone marrow transplantation.
[49] J. Bavaria,et al. Analysis of Epstein-Barr virus-associated posttransplantation lymphoproliferative disorder after lung transplantation. , 1996, Surgery.
[50] L. Robison,et al. Malignant neoplasms following bone marrow transplantation. , 1996, Blood.
[51] G. Heller,et al. The development of cellular immunity to Epstein-Barr virus after allogeneic bone marrow transplantation. , 1996, Blood.
[52] C. Sample,et al. Epstein-Barr Virus DNA recombination and loss in sporadic Burkitt's lymphoma. , 1996, The Journal of infectious diseases.
[53] R. Fisher,et al. Aggressive treatment for postcardiac transplant lymphoproliferation. , 1995, Blood.
[54] N. Harris,et al. Posttransplantation lymphoproliferative disorders in solid organ recipients are predominantly aggressive tumors of host origin. , 1995, American journal of clinical pathology.
[55] A. Fischer,et al. Lymphoproliferative disorders after organ transplantation: a report of 24 cases observed in a single center. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[56] S. Todo,et al. Intestinal transplantation: 4-year experience. , 1995, Transplantation proceedings.
[57] E. Cesarman,et al. Correlative morphologic and molecular genetic analysis demonstrates three distinct categories of posttransplantation lymphoproliferative disorders , 1995 .
[58] R. Krance,et al. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation , 1995, The Lancet.
[59] R. Krance,et al. Early identification of Epstein‐Barr virus‐associated post‐transplantation lymphoproliferative disease , 1995, British journal of haematology.
[60] E. Cesarman,et al. Correlative morphologic and molecular genetic analysis demonstrates three distinct categories of posttransplantation lymphoproliferative disorders. , 1995, Blood.
[61] L. Young,et al. Epstein-Barr virus latency in blood mononuclear cells: analysis of viral gene transcription during primary infection and in the carrier state , 1994, Journal of virology.
[62] H. Heslop,et al. Donor T cells to treat EBV-associated lymphoma. , 1994, The New England journal of medicine.
[63] V. Leblond,et al. Patterns of Epstein-Barr virus latent and replicative gene expression in Epstein-Barr virus B cell lymphoproliferative disorders after organ transplantation. , 1994, Transplantation.
[64] S. Riddler,et al. Increased levels of circulating Epstein-Barr virus (EBV)-infected lymphocytes and decreased EBV nuclear antigen antibody responses are associated with the development of posttransplant lymphoproliferative disease in solid-organ transplant recipients. , 1994, Blood.
[65] C. Alfieri,et al. Direct correlation between the load of Epstein-Barr virus-infected lymphocytes in the peripheral blood of pediatric transplant patients and risk of lymphoproliferative disease. , 1994, Blood.
[66] M. Ladanyi,et al. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. , 1994, The New England journal of medicine.
[67] C. Alfieri,et al. Direct correlation between the load of Epstein-Barr virus-infected lymphocytes in the peripheral blood of pediatric transplant patients and risk of lymphoproliferative disease , 1994 .
[68] L. Young,et al. Epstein-Barr virus and Hodgkin's disease: transcriptional analysis of virus latency in the malignant cells , 1993, The Journal of experimental medicine.
[69] B. Birmingham. Epstein-Barr Virus and Hodgkin's Disease: Transcriptional Analysis of Virus Latency in the Malignant Cells By E. M. Deacon, G. Pallesen,* G. Niedobitek,~ J. Crocker, g L. Brooks, A. B. Rickinson, and L. S. Young , 1993 .
[70] A. Bitsch,et al. Detection and quantification of latently infected B lymphocytes in Epstein-Barr virus-seropositive, healthy individuals by polymerase chain reaction , 1992, Journal of clinical microbiology.
[71] D. Rowe,et al. Epstein-Barr virus latent gene expression in uncultured peripheral blood lymphocytes , 1992, Journal of virology.
[72] Q Y Yao,et al. Epstein-Barr virus latent gene transcription in nasopharyngeal carcinoma cells: coexpression of EBNA1, LMP1, and LMP2 transcripts , 1992, Journal of virology.
[73] E. Kieff,et al. Restricted Epstein-Barr virus protein expression in Burkitt lymphoma is due to a different Epstein-Barr nuclear antigen 1 transcriptional initiation site. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[74] A. Fischer,et al. Anti-B-cell monoclonal antibodies in the treatment of severe B-cell lymphoproliferative syndrome following bone marrow and organ transplantation. , 1991, The New England journal of medicine.
[75] U. Nater,et al. Epstein-Barr virus. , 1991, The Journal of family practice.
[76] J. Cohen. Epstein‐Barr Virus Lymphoproliferative Disease Associated with Acquired Immunodeficiency , 1991, Medicine.
[77] I. Ernberg,et al. Expression of epstein‐barr virus‐encoded growth‐transformation‐associated proteins in lymphoproliferations of bone‐marrow transplant recipients , 1991, International journal of cancer.
[78] R. Fisher,et al. Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients. , 1990, The New England journal of medicine.
[79] M. Rowe,et al. Epstein‐barr virus‐infected b cells persist in the circulation of acyclovir‐treated virus carriers , 1989, International journal of cancer.
[80] I. Ernberg,et al. Eradication of Epstein-Barr virus by allogeneic bone marrow transplantation: implications for sites of viral latency. , 1988, Proceedings of the National Academy of Sciences of the United States of America.
[81] B. Burke,et al. Epstein-Barr virus associated B cell lymphoproliferative disorders following bone marrow transplantation. , 1988, Blood.
[82] J. Finlay,et al. B Cell Lymphoproliferative Disorders Following T Cell Depleted Allogeneic Bone Marrow Transplantation , 1988 .
[83] H. Strander,et al. Characterization of ebv‐carrying b‐cell populations in healthy seropositive individuals with regard to density, release of transforming virus and spontaneous outgrowth , 1987, International journal of cancer.
[84] R. Simmons,et al. Epstein-Barr virus, immunodeficiency, and B cell lymphoproliferation. , 1985, Transplantation.
[85] T. Starzl,et al. REVERSIBILITY OF LYMPHOMAS AND LYMPHOPROLIFERATIVE LESIONS DEVELOPING UNDER CYCLOSPORIN-STEROID THERAPY , 1984, The Lancet.
[86] W. Henle,et al. Antibodies to Epstein-Barr virus-associated nuclear antigen in infectious mononucleosis. , 1974, The Journal of infectious diseases.